

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBLT/CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014 WB

DESPATCHED ON 16TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A29; B7, B44; Cw7, Cw16; DR15, DR4; DQ6, DQ7

Summary of Results					Summary of Results				
Total tested	22	23	23	22	14	15	15	14	
Positive	14	0	7	0	8	0	1	0	
Negative	8	23	16	22	6	15	14	14	
Not Tested / Equivocal	4	3	3	4	4	3	3	4	
% Positive	63.6%	0.0%	30.4%	0.0%	57.1%	0.0%	6.7%	0.0%	
% Negative	36.4%	100.0%	69.6%	100.0%	42.9%	100.0%	93.3%	100.0%	
Consensus	Not Assessed	Negative	Not Assessed	Negative	Not Assessed	Negative	Negative	Negative	
HLA Antibody (Defined By CDC)	Bw6	DQ3	DR7,DQ2	A32,B44,DR7					
Lab No.	Serum 1	Without DTT			With DTT (Not assessed)				Comments
		Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
114	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	
117	Positive	Negative	Positive	Negative					
126	Negative	Negative	Positive	Negative					
136	Positive	Negative	Positive	Negative					
145	Negative	Negative	Negative	Negative					
162	Positive	Negative	Negative	Negative					
163	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	
164	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
169	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
186	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
202	NT	NT	NT	NT	NT	NT	NT	NT	
204	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
206	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
210	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
223	Positive	Negative	Negative	Negative					
227	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell sensitivity to complement dependant cytotoxicity
235	Positive	Negative	Negative	NT	Positive	Negative	Negative	NT	Cell viability was very low
243	Positive	Negative	Negative	Negative					
245	Equivocal	Negative	Positive	Negative	Equivocal	Negative	Negative	Negative	
252	NT	NT	NT	NT	NT	NT	NT	NT	Very low cell viability
259	Positive	Negative	Negative	Negative					
268	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
284	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
293	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
311	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014 WB

DESPATCHED ON 16TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells		pre C'	post C'	
114	1	1	4	1	1	1	1	1	18-Sep	19-Sep		Yes	Yes		In-House	30	60	EB/AO
117	4	1	4	1					19-Sep	19-Sep	Yes		No	80	Pel-Freeze	60	120	Fluoroquench
126									17-Sep	18-Sep		Yes	Yes	100	Cedarlane	30	40	EB/AO
136	8	1	4	1					18-Sep	18-Sep	Yes		Yes	95	In-House	60	60	EB/AO
145									17-Sep	18-Sep		Yes	Yes	100	Invitrogen	45	45	EB/AO
162	1:1								17-Sep	18-Sep		Yes	Yes	100	Cedarlane	60	60	
163	1	1	4	1	1	1	1	1	17-Sep	17-Sep		Yes	Yes	98	Cedarlane	30	60	Fluoroquench
164									17-Sep	18-Sep		Yes	Yes	90	Servibio	45	90	Fluoroquench
169	1	1	4	1	1	1	4	1	18-Sep	19-Sep		Yes	No	97	One Lambda	35	75	Fluoroquench
186	8	0	2	0	8	0	0	0	17-Sep	17-Sep		Yes	Yes	98	Invitrogen	30	60	EB
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
204	4	1	1	1	4	1	1	1	17-Sep	17-Sep		Yes	No	90	Cedarlane	45	90	Fluoroquench
206	4	1	1	1	4	1	1	1	17-Sep	18-Sep		Yes	Yes	95	Cedarlane	30	45	Fluoroquench
210	0	0	0	0	0	0	0	0	19-Sep	19-Sep		Yes	Yes	100	BioRad	30	60	
223	6	1	1	1					18-Sep	19-Sep		Yes	Yes	95	BioRad	45	60	EB/AO
227	NT	NT	NT	NT	NT	NT	NT	NT	17-Sep	17-Sep		Yes	Yes	97	Immucor	30	60	Fluoroquench
235	4	1	1	NT	2	1	1	NT	17-Sep	17-Sep	Yes		No	85	BioRad	30	60	
243	6	1	1	1					18-Sep	19-Sep	Yes		Yes	90	BioRad	30	60	Fluoroquench
245		1	4	1		1	1	1	17-Sep	17-Sep	Yes	Yes	Yes	100	BAG	30	60	EB/AO
252	NT	NT	NT	NT	NT	NT	NT	NT	18-Sep	18-Sep		Yes	Yes	20	One Lambda	30	60	
259									18-Sep	19-Sep	Yes	Yes	Yes	80	BioRad	30	60	AO/PI
268	4	1	1	1	6	1	1	1	17-Sep	18-Sep		Yes	No	98	Gentrak	30	60	EB/AO
284	1	1	1	1	1	1	1	1	17-Sep	18-Sep		Yes	Yes	98	Cedarlane	40	60	EB/AO
293									18-Sep	18-Sep		Yes	Yes	60	Invitrogen	60	120	Eosin
294	4	0	0	0	4	0	0	0	17-Sep	18-Sep		Yes	Yes		Pel-Freeze	30	30	Fluoroquench
311	6				6				17-Sep	17-Sep		Yes	Yes	100	Servibio	30	60	Fluoroquench

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014 WB

DESPATCHED ON 16TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A29; B7, B44; Cw7, Cw16; DR15, DR4; DQ6, DQ7

Summary of Results					Summary of Results				
Total tested	19	20	20	19	13	14	14	14	
Positive	14	6	18	4	8	2	3	0	
Negative	5	14	2	15	5	12	11	14	
Not Tested / Equivocal	4	3	3	4	4	3	3	3	
% Positive	73.7%	30.0%	90.0%	21.1%	61.5%	14.3%	21.4%	0.0%	
% Negative	26.3%	70.0%	10.0%	78.9%	38.5%	85.7%	78.6%	100.0%	
Consensus	Not Assessed	Not Assessed	Positive	Negative	Not Assessed	Negative	Negative	Negative	
HLA Antibody (Defined By CDC)	Bw6	DQ3	DR7,DQ2	A32,B44,DR7					
Lab No.	Serum 1	Without DTT			With DTT (Not assessed)				Comments
		Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
114	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Serum 4 NT due low cell viability
126	Positive	Positive	Positive	NT					
145	Positive	Negative	Positive	Negative					
162	Positive	Positive	Positive	Negative					
163	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	
164	Positive	Positive	Positive	Positive	Positive	Positive	Negative	Negative	
169	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
186	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	
202	NT	NT	NT	NT	NT	NT	NT	NT	
204	Positive	Positive	Positive	Positive	Positive	Positive	Negative	Negative	
206	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	
210	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
223	Positive	Negative	Positive	Negative					
227	NT	NT	NT	NT	NT	NT	NT	NT	
243	Positive	Negative	Positive	Weak Positive					
245	Equivocal	Negative	Positive	Negative	Equivocal	Negative	Negative	Negative	
252	NT	NT	NT	NT	NT	NT	NT	NT	
259	Positive	Negative	Negative	Negative					
268	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
284	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	
293	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	
294	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
311	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	
									Poor cell sensibility to complement dependant cytotoxicity
									Very low cell viability

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A10/2014 WB

DESPATCHED ON 16TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
114	1	1	6	1	1	1	1	1	18-Sep	19-Sep	Yes		One Lambda	30	60	EB/AO
126	75%	75%	100%						17-Sep	18-Sep	Yes	75	Cedarlane	30	40	EB/AO
145	8		8						17-Sep	18-Sep	Yes	100	Invitrogen	45	45	EB/AO
162	1:1	1:1	1:1						17-Sep	18-Sep	Yes	80	Cedarlane	60	60	
163	1	1	6	1	1	1	1	1	17-Sep	17-Sep	Yes	98	Cedarlane	30	60	Fluoroquench
164									17-Sep	18-Sep	Yes	90	Servibio	45	90	Fluoroquench
169	1	1	4	1	1	1	4	1	18-Sep	19-Sep	Yes	97	One Lambda	35	75	Fluoroquench
186	8	4	6	0	6	0	0	0	17-Sep	17-Sep	Yes	99	Invitrogen	30	60	EB
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
204	8	6	8	4	8	4	1	1	17-Sep	17-Sep	Yes	90	Cedarlane	45	90	Fluoroquench
206	6	1	6	4	6	1	6	1	17-Sep	18-Sep	Yes	95	Cedarlane	30	45	Fluoroquench
210	0	0	0	0	0	0	0	0	19-Sep	19-Sep	Yes	80	BioRad	30	60	
223	6	2	8	1					18-Sep	19-Sep	Yes	90	BioRad	45	60	EB/AO
227	NT	NT	NT	NT	NT	NT	NT	NT	17-Sep	17-Sep	Yes	97	Immucor	30	60	Fluoroquench
243	6	1	6	4					18-Sep	19-Sep	Yes	90	BAG	30	60	EB/AO
245		1	8	1		1	1	1	17-Sep	17-Sep	Yes	1000	BAG	30	45	EB/AO
252	NT	NT	NT	NT	NT	NT	NT	NT	18-Sep	18-Sep	Yes	20	One Lambda	30	60	
259									18-Sep	19-Sep	Yes	85	BioRad	30	60	AO/PI
268	8	1	8	1	8	1	1	1	17-Sep	18-Sep	Yes	80	Gentrak	30	60	EB/AO
284	6	2	8	1	8	2	1	1	17-Sep	18-Sep	Yes	93	Cedarlane	40	60	EB/AO
293			6						18-Sep	18-Sep	Yes	40	Invitrogen	60	120	Eosin
294	6	0	4	0	6	0	4	0	17-Sep	18-Sep	Yes		Pel-Freeze	30	30	Fluoroquench
311	6	4	6		6				17-Sep	17-Sep	Yes	100	Servibio	30	60	Fluoroquench

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate